Are Clearside Biomedical Inc. (NASDAQ:CLSD) shares too expensive at this price?

In the latest session, Clearside Biomedical Inc. (NASDAQ: CLSD) closed at $1.18 up 3.51% from its previous closing price of $1.14. In other words, the price has increased by $+0.0400 from its previous closing price. On the day, 278694 shares were traded. CLSD stock price reached its highest trading level at $1.1900 during the session, while it also had its lowest trading level at $1.1115.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



For a deeper understanding of Clearside Biomedical Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.50 and its Current Ratio is at 10.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On July 29, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.

On May 13, 2020, ROTH Capital started tracking the stock assigning a Buy rating and target price of $8.ROTH Capital initiated its Buy rating on May 13, 2020, with a $8 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 17 when Hutson Nancy J bought 30,000 shares for $1.33 per share. The transaction valued at 39,900 led to the insider holds 83,000 shares of the business.

Deignan Charles A. sold 8,833 shares of CLSD for $18,461 on Jan 19. The Chief Financial Officer now owns 351,366 shares after completing the transaction at $2.09 per share. On Jan 19, another insider, Ciulla Thomas, who serves as the Chief Medical Officer of the company, sold 9,050 shares for $2.13 each. As a result, the insider received 19,276 and left with 295,260 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 2.97 while its Price-to-Book (P/B) ratio in mrq is 3.81.

Stock Price History:

Over the past 52 weeks, CLSD has reached a high of $4.12, while it has fallen to a 52-week low of $1.00. The 50-Day Moving Average of the stock is 1.2266, while the 200-Day Moving Average is calculated to be 1.5497.

Shares Statistics:

For the past three months, CLSD has traded an average of 182.58K shares per day and 533.42k over the past ten days. A total of 60.19M shares are outstanding, with a floating share count of 53.55M. Insiders hold about 11.02% of the company’s shares, while institutions hold 28.60% stake in the company. Shares short for CLSD as of Oct 13, 2022 were 495.81k with a Short Ratio of 0.53M, compared to 520.3k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.82% and a Short% of Float of 0.91%.

Earnings Estimates

There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.03 for the current quarter, with a high estimate of $0.39 and a low estimate of -$0.15, while EPS last year was -$0.08. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.12 and low estimates of -$0.16.

Analysts are recommending an EPS of between -$0.02 and -$0.57 for the fiscal current year, implying an average EPS of -$0.43. EPS for the following year is -$0.62, with 5 analysts recommending between -$0.53 and -$0.8.

Revenue Estimates

A total of 4 analysts have provided revenue estimates for CLSD’s current fiscal year. The highest revenue estimate was $33.23M, while the lowest revenue estimate was $700k, resulting in an average revenue estimate of $8.9M. In the same quarter a year ago, actual revenue was $29.57M, down -69.90% from the average estimate.